Loading
Latest filing published 17 Apr 2024 for Outlook Therapeutics, Inc..
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Syntone Ventures LLC on record concern Outlook Therapeutics, Inc. We count 3 filings; the first trade dates from 15 July 2020 and the latest from 15 April 2024.
The open-market record is one-sided, with 3 purchases worth €3.4M and not one sale. The totals do not cover 1 filing with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2024 alone, the filings show 1 purchase and no sales.
Of 3 purchases, 1 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
On 17 April 2024 came the latest disclosure, an open-market purchase in Outlook Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations